Cubist Systematic Strategies LLC Reduces Position in Kezar Life Sciences, Inc. (NASDAQ:KZR)
Cubist Systematic Strategies LLC Reduces Position in Kezar Life Sciences, Inc. (NASDAQ:KZR)
Cubist Systematic Strategies LLC lowered its holdings in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) by 21.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,220 shares of the company's stock after selling 20,335 shares during the quarter. Cubist Systematic Strategies LLC owned 0.12% of Kezar Life Sciences worth $639,000 as of its most recent SEC filing.
據該公司在最近的 13F 與證券交易委員會提交的文件中表示，立體派系統策略有限責任公司在第三季度將其在凱扎爾生命科學公司（NASDAQ：KZR-獲得評級）的股份持有量下降了 21.5％。該公司在本季度賣出 20,335 股股票後，擁有該公司股票 74,220 股。立體主義系統策略有限責任公司擁有克扎爾生命科學的 0.12％，價值 639,000 美元，截至最近的 SEC 文件。
Other hedge funds also recently bought and sold shares of the company. Great West Life Assurance Co. Can bought a new stake in Kezar Life Sciences during the 3rd quarter valued at about $26,000. Tower Research Capital LLC TRC raised its position in Kezar Life Sciences by 88.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company's stock valued at $58,000 after purchasing an additional 3,190 shares in the last quarter. Robeco Institutional Asset Management B.V. bought a new position in shares of Kezar Life Sciences during the 3rd quarter worth $68,000. ProShare Advisors LLC bought a new stake in shares of Kezar Life Sciences in the third quarter valued at about $100,000. Finally, Virtu Financial LLC purchased a new position in Kezar Life Sciences during the 3rd quarter valued at about $104,000. Institutional investors own 84.03% of the company's stock.
其他對沖基金最近也買賣了該公司的股票。大西部人壽保險公司可以在第三季度買入 Kezar 生命科學的新股份，價值約為 26,000 美元。塔研究資本有限責任公司 TRC 在第三季度提高了其在凱扎爾生命科學的地位 88.9％。高塔研究資本有限責任公司 TRC 現在擁有 6,777 股，價值為 58,000 美元的公司股票，價值在上個季度額外購買 3,190 股之後。荷寶機構資產管理 BV. 在第三季度買入了克扎爾生命科學股份的新頭寸，價值 68,000 美元。ProShare 顧問有限責任公司在第三季度購買了克薩爾生命科學股份的新股份，價值約為 100,000 美元。最後，Virtu 金融有限責任公司在第三季度收購了克扎爾生命科學的新職位，價值約為 104,000 美元。機構投資者擁有公司股票的 84.03%。
Kezar Life Sciences Price Performance
凱扎爾生命科學價格表現
Shares of NASDAQ KZR opened at $4.64 on Friday. The company has a market cap of $317.28 million, a PE ratio of -4.59 and a beta of 0.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 31.15 and a current ratio of 31.15. The business has a 50-day simple moving average of $6.46 and a two-hundred day simple moving average of $7.45. Kezar Life Sciences, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $18.55.
納斯達克 KZR 的股票上週五以 4.64 美元開盤。該公司的市值為 317.28 萬美元，私募股權比率為 -4.59，測試版為 0.25。該公司的債務與權益比率為 0.03，快速比率為 31.15，流動比率為 31.15。該業務有一個 50 天的簡單移動平均線 6.46 美元和兩百天的簡單移動平均線 7.45 美元。凱薩生命科學公司擁有五十二周低點 4.30 美元，五十二周高點為 18.55 美元。
Insider Activity at Kezar Life Sciences
凱扎爾生命科學的內幕活動
In related news, major shareholder Morningside Venture Investment sold 25,000 shares of the company's stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $7.15, for a total value of $178,750.00. Following the sale, the insider now owns 5,487,993 shares in the company, valued at $39,239,149.95. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 248,276 shares of company stock valued at $1,708,683 in the last ninety days. Company insiders own 7.80% of the company's stock.
在相關消息中，主要股東晨興創業投資在 2 月 3 日（星期五）發生的一項交易中出售了該公司股票 25,000 股。該股票以 7.15 美元的平均價格出售，總價值為 178,750.00 美元。出售後，內幕人士現在擁有該公司的 5,487,993 股股份，價值為 39,239,149.95 美元。該銷售在與 SEC 合法提交的文件中披露，該文件可通過以下方式獲得 這個鏈接。在過去九十天內，內部人員總共出售了 248,276 股公司股票，價值為 1,708,683 美元。公司內部人士擁有公司股票的 7.80％。
Analyst Upgrades and Downgrades
分析師升級和降級
Separately, Wells Fargo & Company lowered their target price on Kezar Life Sciences from $17.00 to $14.00 and set an "overweight" rating for the company in a report on Tuesday, January 3rd.
另外，富國銀行公司將克扎爾生命科學的目標價格從 17.00 美元降至 14.00 美元，並在 1 月 3 日（週二）的一份報告中為該公司設定了「超重」評級。
Kezar Life Sciences Company Profile
凱扎爾生命科學公司簡介
(Get Rating)
(取得評分)
Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.
Kezar Life Sciences, Inc 是一家臨床階段的生物製藥公司，致力於在南三藩市和加利福尼亞州開發新型小分子治療藥物以治療自身免疫和癌症。其產品線包括 KZR-616、KZR-261 和 KZR-待定。該公司由約翰·福勒成立, 克里斯托弗 Ĵ.
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- 免費索取凱扎爾生命科學研究報告
- SVB 金融崩潰對美國銀行意味著什麼
- 市場節拍週的回顧 — 3/6 — 3/10
- 2 海上鑽探股票將提取巨額利潤
- 前面有兩位數字的三個主要股票
- 投資者可以信任消費者提升美國戶外品牌嗎？
Want to see what other hedge funds are holding KZR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating).
想看看還有哪些對沖基金持有 KZR？ 訪問 Holdingschannel.com 以獲取凱扎爾生命科學公司（納斯達克：KZR-獲得評分）的最新 13 樓文件和內幕交易。
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收凱扎爾生命科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Kezar 生命科學及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。